Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.

Roche’s multiple sclerosis superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year. Now, one major obstacle on the drug's blockbuster journey—England's ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...

- The trial did not meet its primary endpoint; results support Ocrevus IV 600 mg as the optimal dose to slow disability progression - - High dose was well tolerated with an overall comparable safety ...

Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) can cause mild to serious side effects. More common side effects include respiratory infections (upper and lower). If ...

England’s cost watchdogs are standing by their controversial decision to reject Roche’s Ocrevus in a form of multiple sclerosis for which it's the only approved treatment. Roche says pricing isn't to ...

Credit: Genentech Ocrevus Zunovo is supplied in a single-dose vial containing 920mg of ocrelizumab and 23,000 units hyaluronidase per 23mL. Ocrevus Zunovo is a combination of ocrelizumab, a ...

– 75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to Ocrevus in open-label ...

EXTON, Pa., March 10, 2020 /PRNewswire/ -- In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for the treatment of relapsing ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease ...